Internal Medicine

Questions discussed in this category

What work up do you pursue for a thorough evaluation in patients that present with a potential diagnosis of dermatitis artefacta?

3 Answers available

How do you manage withdrawal symptoms of SNRIs that exist even after slow taper?

2 Answers available

Have you observed adverse mental health side effects in patients who start montelukast?

In light of the FDA warning about mental health side effects of the medication have you observed in particular any patients develop suicidal thoughts ...

3 Answers available

For a patient with known CAD and low baseline HDL, would a PCSK9 inhibitor be a better option than a statin, given concerns for paradoxical lowering of HDL levels with statin therapy that we can encounter in the outpatient clinical setting?

4 Answers available

Would you still consider omalizumab for CSU with angioedema in a patient with Factor V Leiden deficiency?

Omalizumab has been reported as a possible provoking factor for venous thromboembolism.

2 Answers available

Do you routinely recommend transition to dual PO antibiotic coverage for strep species and MRSA, for patients with purulent cellulitis and in the absence of culture data?

2 Answers available

For optimal GDMT for patients with HFrEF and co-existing ESRD, is there evidence to support the use of SGLT2 inhibitors and/or ARB/ARNI?

1 Answer available

Besides treadmill, what other exercises may be considered for post-exercise ABIs, and are their diagnostic parameters identical to standard post-exercise ABIs?

1 Answer available

What are standard selection criteria for patients who are eligible for heart transplantation?

1 Answer available

What treatment combination approach would you recommend for mucous membrane pemphigoid?

2 Answers available

Do you use dual anti-platelet therapy inpatients with low NIHSS who have had bilateral brainstem strokes?

1 Answer available

In the treatment of lupus nephritis, which patients may benefit from the use of rituximab or other B-cell depleting agents during induction?

This question is part of a collaboration with RheumMadness and is specifically in reference to: Obinutuzumab in Lupus Nephritis

2 Answers available

How do you utilize anifrolumab for SLE in your practice?

This question is part of a collaboration with RheumMadness and is specifically in reference to: Long-term outcomes of anifrolumab in SLE.

2 Answers available

How do you manage emotional blunting due to SSRIs/SNRIs?

7 Answers available

Given the data from SWOG 1826 suggesting that Nivo-AVD is likely the preferred regimen for advanced Hodgkin lymphoma patients, are there scenarios where alternative regimens may still be preferred?

When now would you consider regimens such as BV-AVD or BrECADD in advanced stage HL?

1 Answer available

Papers discussed in this category

Arthritis and rheumatism, 2012-04

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.

Ann Rheum Dis, 2013 Jun 05

Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids.

Annals of the rheumatic diseases, 2021 Oct 06

B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial.

The New England journal of medicine, 2025 Feb 07

Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis.

Autoimmunity reviews, 2009-02

The risk of ultraviolet radiation exposure from indoor lamps in lupus erythematosus.

Journal of the American Academy of Dermatology, 2011-05

Quality of life in cutaneous lupus erythematosus.

Arthritis and rheumatism, 2013-07

Vitamin D in systemic lupus erythematosus: modest association with disease activity and the urine protein-to-creatinine ratio.

Arthritis Rheumatol, 2021 Mar 24

Long-Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open-Label Extension Study.

Rev Med Interne, 2016 Oct 13

[Blood concentration of hydroxychloroquine in systemic lupus erythematosus care: Usefulness and limits].

Arthritis Care Res (Hoboken), 2021 Mar 30

Clinical Significance of Monitoring Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis.

JAMA Dermatol,

Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study.

Mod Rheumatol, 2020 Sep 17

Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials.

Ann Rheum Dis, 2014 Feb 13

The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort.

Ann Rheum Dis, 2019 Jan 04

Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis.

Ann Rheum Dis, 2014 Apr 16

Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.

Arthritis & rheumatology (Hoboken, N.J.), 2023 Jun 01

Comparative Risks of Infection With Belimumab Versus Oral Immunosuppressants in Patients With Nonrenal Systemic Lupus Erythematosus.

Annals of the rheumatic diseases, 2023 Oct 12

EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.

Lupus science & medicine, 2024 May 22

Disease-modifying therapies in systemic lupus erythematosus for extrarenal manifestations.

The Lancet. Rheumatology, 2019 Nov 25

Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study.

N Engl J Med, 2019 Dec 18

Trial of Anifrolumab in Active Systemic Lupus Erythematosus.

J Heart Lung Transplant, 2024 Oct

International Society for Heart and Lung Transplantation Guidelines for the Evaluation and Care of Cardiac Transplant Candidates-2024.

Stroke, 2013-12

CHANCE trial: early short-term dual antiplatelet treatment for stroke prevention.

The New England journal of medicine, 2014-09-11

Angiotensin-neprilysin inhibition versus enalapril in heart failure.

Circulation, 2022 Apr 01

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

The New England journal of medicine, 2019 Sep 19

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.

The New England journal of medicine, 2020 Aug 28

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.

Related Topics